Bladder cancer drug combo trial pulled before it even started
NCT ID NCT05564416
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial was designed to test two drugs—erdafitinib and atezolizumab—for people with muscle invasive bladder cancer who cannot take the standard chemotherapy drug cisplatin. Erdafitinib targets a specific gene change that can drive cancer growth, while atezolizumab helps the immune system attack cancer cells. The study was withdrawn before any patients were enrolled, so no data were collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- erdafitinib and atezolizumab
- What this could lead to
- If successful, this could point toward a new treatment option for bladder cancer patients who cannot receive standard chemotherapy.
- What could go wrong
- The trial was withdrawn before enrolling any participants, so no results are available. It is unclear if the approach would be effective or safe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Bladder cancer: a new combo aims to avoid radical surgery
- Can a targeted antibody-drug combo tackle rare bladder cancers?
- A simple blood draw could detect bladder Cancer's return — a trial puts it to the test
- Can a new nucleotide analogue boost cancer treatment?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Can a Two-Drug attack shrink Hard-to-Treat bladder tumors?